List of Excipients in Branded Drug MARAVIROC

Generic Drugs Containing MARAVIROC

Company	Ingredient	NDC	Excipient
Camber Pharmaceuticals Inc	maraviroc	31722-579	CELLULOSE, MICROCRYSTALLINE
Camber Pharmaceuticals Inc	maraviroc	31722-579	LACTOSE MONOHYDRATE
Camber Pharmaceuticals Inc	maraviroc	31722-579	LECITHIN, SOYBEAN
Camber Pharmaceuticals Inc	maraviroc	31722-579	MAGNESIUM STEARATE
Camber Pharmaceuticals Inc	maraviroc	31722-579	POLYETHYLENE GLYCOL
Camber Pharmaceuticals Inc	maraviroc	31722-579	POLYVINYL ALCOHOL
Camber Pharmaceuticals Inc	maraviroc	31722-579	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in MARAVIROC?

# Of NDCs	Excipient
5	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
9	CELLULOSE, MICROCRYSTALLINE
3	FD&C BLUE NO. 2
3	HYDROGENATED SOYBEAN LECITHIN
2	HYPROMELLOSE 2910
4	LACTOSE MONOHYDRATE
3	LECITHIN, SOYBEAN

Maraviroc Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Maraviroc is an oral CCR5 antagonist with an established tablet formulation, expired U.S. regulatory exclusivity, and a commercial profile shaped by generic competition, limited treatment share, CYP3A-mediated drug interactions, and the need for flexible dosing. The strongest excipient opportunities are improved dissolution, lower-dose tablets, pediatric and geriatric liquid formulations, and differentiated products for markets where HIV treatment access remains fragmented.

What is maraviroc and how is it used?

Maraviroc is a small-molecule antiretroviral that selectively blocks the CCR5 co-receptor used by CCR5-tropic HIV-1 to enter CD4 cells. It is marketed as Selzentry in the United States and Celsentri in several international markets. Pfizer developed the product; ViiV Healthcare has held commercialization rights in certain markets.

The FDA approved maraviroc in August 2007 for use with other antiretroviral agents in adults infected with CCR5-tropic HIV-1. It is also approved for pediatric patients weighing at least 2 kg under applicable labeling conditions. Tropism testing is required before treatment because maraviroc does not treat patients whose virus uses CXCR4 or mixed tropism [1].

Attribute	Maraviroc
Active ingredient	Maraviroc
Drug class	CCR5 antagonist
Primary indication	Combination treatment of CCR5-tropic HIV-1
Original U.S. brand	Selzentry
International brand	Celsentri
U.S. approval	2007
Dosage forms	Film-coated tablets; oral solution in selected markets
Key metabolic pathways	CYP3A and P-glycoprotein
Generic pathway	Abbreviated New Drug Application, not biosimilar
Core commercial constraint	Requires tropism testing and is generally reserved for treatment-experienced patients

Maraviroc is not a biologic. Biosimilar approval is therefore not relevant. Competitive entry occurs through small-molecule generic procedures, including ANDA filings in the United States and equivalent national procedures elsewhere.

What excipients are used in the marketed maraviroc tablet?

The U.S. Selzentry tablet uses a conventional immediate-release formulation. The FDA prescribing information identifies microcrystalline cellulose, dibasic calcium phosphate, sodium starch glycolate, and magnesium stearate among the tablet excipients. The film coating contains conventional coating materials, including hypromellose, titanium dioxide, and colorants, subject to strength-specific composition [1].

Formulation function	Typical marketed excipient or excipient class	Technical purpose
Diluent and compression aid	Microcrystalline cellulose	Tablet mass, compactability, mechanical strength
Mineral diluent	Dibasic calcium phosphate	Filler, hardness, density
Disintegrant	Sodium starch glycolate	Rapid tablet breakup and dissolution
Lubricant	Magnesium stearate	Ejection from tooling and manufacturing control
Film coating	Hypromellose-based coating system	Protection, swallowability, identification
Pigment or opacifier	Titanium dioxide and colorants	Product identification and light protection

The marketed composition suggests a standard direct-compression or dry-granulation platform rather than a highly specialized delivery system. That creates a relatively low barrier for generic development, but bioequivalence still depends on particle size, polymorphic form, blend uniformity, tablet disintegration, dissolution, and control of excipient variability.

How does maraviroc’s physicochemical profile affect excipient selection?

Maraviroc has formulation characteristics that make dissolution and exposure control important. Its clinical pharmacology is complicated by substantial metabolism and transporter effects. The drug is a substrate of CYP3A and P-glycoprotein, and strong inhibitors or inducers can require dose adjustment [1].

Excipient selection should therefore prioritize:

1. Consistent dissolution across physiological pH conditions.
2. Low batch-to-batch variability in drug release.
3. Compatibility with CYP3A and transporter-sensitive pharmacokinetics.
4. Robust tablet performance at 150 mg and 300 mg strengths.
5. A formulation that does not introduce clinically meaningful food effects.
6. Low-cost manufacturing suitable for generic and emerging-market supply.

A solubility-enhancing excipient may increase dissolution but can also alter apparent exposure. For maraviroc, a formulation developer should evaluate whether surfactants, lipid excipients, cyclodextrins, or amorphous dispersions change the relationship between in vitro dissolution and in vivo exposure. The preferred strategy is usually the least complex formulation that achieves rapid, reproducible release.

What excipient strategies are available for generic maraviroc?

Conventional immediate-release tablets

The lowest-risk strategy is to reproduce the functional excipient architecture of the reference product without copying non-protected trade dress. A generic developer can use:

• Microcrystalline cellulose or an equivalent compressible filler.
• Dibasic calcium phosphate or another mineral diluent.
• Sodium starch glycolate, crospovidone, or croscarmellose sodium as disintegrant.
• Magnesium stearate or another accepted lubricant.
• A standard hypromellose film coat.

The commercial advantage is low cost and established manufacturing equipment. The main technical risk is achieving dissolution equivalence at both tablet strengths while maintaining hardness, friability, and stability.

Direct-compression formulation

Direct compression can reduce processing steps and improve manufacturing economics. It is appropriate where maraviroc has adequate flow and blend uniformity. The formulation must control segregation because the active pharmaceutical ingredient may represent a material fraction of the tablet mass at lower strength.

Potential excipient variables include:

• Particle-size distribution of microcrystalline cellulose.
• Grade and viscosity of the disintegrant.
• Lubrication time and magnesium stearate concentration.
• Dicalcium phosphate grade and moisture content.
• Compression force and tablet porosity.

Excessive lubrication can slow wetting and dissolution. Excessive compression can reduce porosity and delay tablet breakup.

Wet granulation or dry granulation

Granulation may improve content uniformity and flow when the active ingredient has poor powder handling properties. Dry granulation avoids water and may reduce hydrolytic stress. Wet granulation can improve compressibility but adds process complexity and may require tighter control of residual moisture.

For a generic product, granulation is commercially justified only if direct compression cannot reliably meet dissolution and uniformity specifications. The additional process steps increase validation cost and may reduce the price advantage over a simple tablet.

Solubility-enhanced systems

A more differentiated formulation could use:

• Surfactants.
• Co-solvents.
• Cyclodextrin complexes.
• Amorphous solid dispersions.
• Polymer-based precipitation inhibitors.
• Lipid-based delivery systems.
• Nanocrystal or particle-size-reduction technology.

These systems may support a lower-dose tablet or oral liquid. They also create additional regulatory and manufacturing burdens. A formulation patent could be possible if the excipient ratio, process, particle structure, or dissolution profile is novel and non-obvious. The commercial value depends on whether the formulation produces a measurable clinical or adherence benefit.

What formulations are protected by maraviroc patents?

The public FDA label establishes the marketed dosage forms and excipients but does not, by itself, define enforceable patent scope. Maraviroc’s patent estate historically included compound, pharmaceutical composition, and related development rights. Core compound protection and U.S. regulatory exclusivity have expired, leaving generic manufacturers to assess any surviving jurisdiction-specific patents and formulation claims through current patent databases and regulatory records.

The principal commercial distinction is between:

Patent category	Relevance to maraviroc
Compound patents	Historically protected the active molecule and key chemical entities
Salt or solid-form patents	May address crystalline form, purity, or stability
Tablet composition patents	Could cover excipient ratios, release, or dosage form architecture
Oral-solution patents	Could cover solubilization and stability systems
Method-of-use patents	Could address tropism-selected treatment or dosing populations
Manufacturing patents	Could cover synthesis, purification, or crystallization
Packaging patents	Usually lower-value barriers unless stability is difficult

A generic manufacturer should not assume that expiration of the original compound patent eliminates all formulation or process risk. The relevant question is whether any unexpired claim reads on the proposed active form, dosage form, manufacturing process, or labeled use in the target jurisdiction.

When did maraviroc lose exclusivity?

The FDA granted maraviroc five years of new chemical entity exclusivity beginning with the 2007 approval. That period expired in 2012. Any applicable pediatric extension would have added six months to qualifying exclusivity periods, subject to the specific regulatory record [2].

Patent expiry is jurisdiction- and patent-family-specific. In commercial terms, the product has moved from an innovator-protected market to a generic-access market. The most important remaining barriers are not basic regulatory exclusivity. They are:

• Limited market size relative to high-volume antiretrovirals.
• Need for tropism testing.
• Dependence on combination therapy.
• Drug-interaction management.
• Product registration requirements in individual countries.
• Manufacturing economics at modest annual volumes.

What is the Orange Book status of maraviroc?

Selzentry is listed in FDA drug databases as a small-molecule prescription product. The relevant generic pathway is an ANDA referencing the listed drug. Orange Book review should focus on:

• Active patent listings for the applicable strength and dosage form.
• Patent-use codes.
• Any pediatric-exclusivity notation.
• Approved tablet and oral-solution presentations.
• Reference-listed drug status.
• Current marketing status and availability.

An ANDA applicant must address listed patents through certification under the Hatch-Waxman framework. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed. FDA approval may trigger patent litigation if the patent holder files suit within the statutory period.

What Paragraph IV challenges and litigation affect maraviroc?

Maraviroc’s commercial risk is primarily generic-entry risk rather than biosimilar risk. A Paragraph IV challenge would be commercially meaningful only if a relevant Orange Book patent remained enforceable and covered the proposed product or labeling.

The litigation framework is:

Event	Commercial effect
ANDA filing with Paragraph IV certification	Potential early generic approval pathway
Notice to patent holder	Starts the patent holder’s response period
Patent litigation within statutory period	Can impose a 30-month stay on FDA approval, subject to statutory exceptions
Settlement agreement	May establish an agreed generic-entry date or licensing terms
Patent expiration without litigation	Generic approval proceeds subject to FDA review

No broad biosimilar litigation framework applies because maraviroc is not a biologic. The most likely generic disputes would concern listed formulation, method-of-use, or process patents rather than the basic existence of the active molecule.

How strong is the maraviroc patent estate?

The estate is commercially weaker than the patent estate surrounding a recently launched antiretroviral. The original composition-of-matter protection has aged out, and the drug has a narrow treatment position compared with integrase inhibitor-based regimens.

Patent-estate factor	Assessment
Core molecule	Low barrier after expiry of compound protection
Tablet formulation	Moderate only if a live, enforceable claim covers a necessary feature
Oral solution	Potentially stronger if formulation know-how is difficult to reproduce
Method of use	Limited by narrow labeled population and combination-treatment requirements
Manufacturing	Potentially relevant where impurity control or solid form is difficult
Regulatory exclusivity	Expired
Biosimilar barrier	Not applicable
Generic substitution risk	High where products are approved and reimbursed

Formulation patents have greater value when they solve a clinically visible problem, such as pediatric dosing, swallowing difficulty, or stable liquid delivery. A tablet patent that only substitutes one conventional filler for another is less likely to create durable commercial differentiation.

What commercial opportunities exist for maraviroc excipients?

Pediatric oral solution

A stable, palatable oral solution is the clearest formulation opportunity. Pediatric HIV therapy requires weight-based dosing, and tablets can create dose-flexibility and swallowing problems. A liquid formulation could use a buffered aqueous system, cosolvent, surfactant, complexing agent, or polymeric solubilizer.

The development target should include:

• Chemical and physical stability.
• Low microbial risk.
• Acceptable taste.
• Accurate dosing with an oral syringe.
• Compatibility with common pediatric feeding practices.
• Low interaction risk with antiretroviral co-medications.
• Commercially practical packaging and shelf life.

Lower-cost generic tablets

The largest volume opportunity is a cost-efficient generic tablet. Excipients should be selected for global availability, low regulatory complexity, and compatibility with high-throughput compression. A formulation that uses widely accepted excipients can reduce supply-chain risk in low- and middle-income markets.

Fixed-dose or co-packaged therapy

Maraviroc is used with other antiretroviral agents, but fixed-dose combination development is technically and commercially difficult. The co-formulated agents may have different dose ratios, stability requirements, and interaction profiles. Co-packaging may offer a lower-risk alternative to a new fixed-dose tablet.

Abuse-resistant or adherence-oriented packaging

Because maraviroc is a chronic therapy, calendar blister packs, unit-dose packaging, and combination co-packs could improve adherence. Packaging claims generally provide less defensible exclusivity than a new formulation, but they can support procurement contracts and differentiated distribution.

Regional manufacturing and licensing

Generic manufacturers with local registration capabilities may pursue licensing or technology-transfer agreements for:

• Tablet manufacture.
• Oral-solution production.
• Pediatric presentations.
• Regional dossiers.
• Supply to public-sector HIV programs.

The commercial case is strongest in countries where the drug remains clinically useful for patients with limited alternatives and where local procurement values a reliable supply more than a novel formulation.

How does maraviroc compare with competing HIV drugs?

Maraviroc competes with higher-volume antiretroviral classes, particularly integrase strand-transfer inhibitors such as dolutegravir and bictegravir-based regimens. These products generally have broader use and simpler treatment positioning.

Factor	Maraviroc	Integrase inhibitor regimens
Viral tropism testing	Required	Generally not required
Treatment position	More specialized	Broad first-line and treatment use
Main formulation opportunity	Pediatric liquid and generic tablet	Fixed-dose combinations and long-acting systems
Generic market size	More limited	Larger for high-volume agents
Interaction profile	CYP3A and P-gp sensitive	Agent-specific, often simpler
Commercial differentiation	Tropism-selected therapy	Broad efficacy, convenience, and combination products

Maraviroc’s advantage is targeted activity against CCR5-tropic virus. Its commercial weakness is that the target population is restricted and treatment selection requires diagnostic confirmation.

What generic launch scenarios exist for maraviroc?

Scenario 1: Conventional tablet entry

A manufacturer launches 150 mg and 300 mg immediate-release tablets after ANDA approval. This is the most likely route because it minimizes formulation and manufacturing complexity.

Scenario 2: Single-strength entry

A generic manufacturer initially launches one strength to reduce inventory and validation cost. This may limit uptake because clinicians often require dose adjustment based on interacting medicines and concomitant therapy.

Scenario 3: Pediatric liquid entry

A specialized manufacturer launches an oral solution or suspension. The addressable market is smaller, but the product may face less direct competition and qualify for institutional procurement opportunities.

Scenario 4: Regional license or supply agreement

A manufacturer obtains rights for selected countries rather than competing globally. This model can support local registration while avoiding the cost of a broad multinational launch.

Scenario 5: Limited commercial entry

Even after approval, a generic manufacturer may not launch because the market is too small, the reference product is available at a discount, or supply-chain costs exceed expected margin. Approval and actual market entry are separate commercial events.

What manufacturing and IP barriers remain?

The active ingredient can be manufactured through a multi-step synthetic process requiring control of stereochemistry, impurities, residual solvents, and solid-state properties. Manufacturing patents may have less practical force after expiry, but process know-how can still affect cost and quality.

The principal technical barriers are:

• Control of active-ingredient impurity profile.
• Reproducible particle size.
• Stable tablet compression.
• Rapid and consistent dissolution.
• Protection from moisture and light where required.
• Compatibility with film-coating systems.
• Reliable supply of qualified excipients.
• Validation of drug-interaction-relevant exposure.

For an oral solution, the barriers increase because solubilization, precipitation, taste, microbial preservation, container compatibility, and dose-measurement accuracy must be demonstrated together.

Key Takeaways

• Maraviroc is a small-molecule CCR5 antagonist, so generic competition uses the ANDA pathway rather than biosimilar regulation.
• The marketed tablet uses conventional excipients, including microcrystalline cellulose, dibasic calcium phosphate, sodium starch glycolate, and magnesium stearate.
• The highest-value formulation opportunity is a stable, palatable pediatric oral solution.
• A low-cost immediate-release tablet remains the most practical generic strategy.
• Solubility-enhancing systems may create formulation differentiation but increase development and regulatory complexity.
• U.S. NCE exclusivity expired in 2012; current patent risk must be assessed by jurisdiction and patent family.
• Tropism testing, treatment-experienced positioning, and CYP3A/P-glycoprotein interactions limit the addressable market.
• No biosimilar pathway applies.
• Generic launch risk is high where registration is available, but actual commercial entry may remain limited by market size.
• Licensing, regional supply, pediatric formulations, and public-sector procurement are the most credible commercial opportunities.

FAQs

Can maraviroc be reformulated as a pediatric suspension?

Yes. A pediatric suspension or solution could address weight-based dosing and swallowing limitations. The formulation would require stability, taste, microbial, dosing-device, and precipitation studies.

Are excipient substitutions in a generic maraviroc tablet permitted?

Yes. An ANDA does not necessarily require identical inactive ingredients, but the proposed formulation must meet applicable pharmaceutical equivalence, bioequivalence, quality, dissolution, and stability requirements.

Is maraviroc suitable for a fixed-dose combination tablet?

Technically possible, but commercially difficult. Dose flexibility, interaction-driven dose adjustments, and compatibility with partner antiretrovirals reduce the attractiveness of a fixed-dose product.

What is the strongest formulation patent opportunity for maraviroc?

A formulation that solves pediatric delivery, improves liquid stability, or demonstrates a clinically relevant exposure or adherence benefit is more defensible than a conventional tablet using alternative fillers.

Does maraviroc have biosimilar competition?

No. Maraviroc is a chemically synthesized small molecule. Competitors seek approval as generic versions through small-molecule regulatory pathways.

References

1. U.S. Food and Drug Administration. (2023). Selzentry (maraviroc) prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations.
3. European Medicines Agency. (2007). Celsentri: EPAR product information.
4. U.S. Food and Drug Administration. (2017). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA.
5. U.S. Food and Drug Administration. (1984). Drug Price Competition and Patent Term Restoration Act of 1984.